• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ODF2L 在卵巢上皮性癌细胞模型中与 WEE1 抑制作用协同致死。

ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models.

机构信息

Department of Obstetrics and Gynecology, The First Affiliated Hospital.

Department of Biochemistry and Molecular Biology, Zhongshan School of Medicine, and.

出版信息

J Clin Invest. 2023 Jan 17;133(2):e161544. doi: 10.1172/JCI161544.

DOI:10.1172/JCI161544
PMID:36378528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9843051/
Abstract

WEE1 has emerged as an attractive target in epithelial ovarian cancer (EOC), but how EOC cells may alter their sensitivity to WEE1 inhibition remains unclear. Here, through a cell cycle machinery-related gene RNAi screen, we found that targeting outer dense fiber of sperm tails 2-like (ODF2L) was a synthetic lethal partner with WEE1 kinase inhibition in EOC cells. Knockdown of ODF2L robustly sensitized cells to treatment with the WEE1 inhibitor AZD1775 in EOC cell lines in vitro as well as in xenografts in vivo. Mechanistically, the increased sensitivity to WEE1 inhibition upon ODF2L loss was accompanied by accumulated DNA damage. ODF2L licensed the recruitment of PKMYT1, a functionally redundant kinase of WEE1, to the CDK1-cyclin B complex and thus restricted the activity of CDK1 when WEE1 was inhibited. Clinically, upregulation of ODF2L correlated with CDK1 activity, DNA damage levels, and sensitivity to WEE1 inhibition in patient-derived EOC cells. Moreover, ODF2L levels predicted the response to WEE1 inhibition in an EOC patient-derived xenograft model. Combination treatment with tumor-targeted lipid nanoparticles that packaged ODF2L siRNA and AZD1775 led to the synergistic attenuation of tumor growth in the ID8 ovarian cancer syngeneic mouse model. These data suggest that WEE1 inhibition is a promising precision therapeutic strategy for EOC cells expressing low levels of ODF2L.

摘要

WEE1 已成为治疗上皮性卵巢癌(EOC)的一个有吸引力的靶点,但 EOC 细胞如何改变其对 WEE1 抑制的敏感性尚不清楚。在这里,我们通过细胞周期机制相关基因 RNAi 筛选,发现靶向精子尾部外致密纤维 2 样(ODF2L)是 EOC 细胞中与 WEE1 激酶抑制的合成致死伙伴。ODF2L 的敲低可显著增强 EOC 细胞系在体外以及体内异种移植模型中对 WEE1 抑制剂 AZD1775 的敏感性。从机制上讲,ODF2L 缺失后对 WEE1 抑制的敏感性增加伴随着 DNA 损伤的积累。ODF2L 允许 PKMYT1(WEE1 的功能冗余激酶)被招募到 CDK1-cyclin B 复合物中,从而限制了 WEE1 被抑制时 CDK1 的活性。临床上,ODF2L 的上调与 CDK1 活性、DNA 损伤水平以及患者来源的 EOC 细胞对 WEE1 抑制的敏感性相关。此外,ODF2L 水平预测了 EOC 患者来源异种移植模型中对 WEE1 抑制的反应。肿瘤靶向脂质纳米粒的联合治疗,将 ODF2L siRNA 和 AZD1775 包装在一起,导致 ID8 卵巢癌同基因小鼠模型中的肿瘤生长协同抑制。这些数据表明,WEE1 抑制是一种很有前途的治疗低水平表达 ODF2L 的 EOC 细胞的精准治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/05bcb7b5bba2/jci-133-161544-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/8187a4e58b65/jci-133-161544-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/c976f210828d/jci-133-161544-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/4c0c45bd6851/jci-133-161544-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/62af543d2c8c/jci-133-161544-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/e6a80e02bb5f/jci-133-161544-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/bdf7d713227a/jci-133-161544-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/05bcb7b5bba2/jci-133-161544-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/8187a4e58b65/jci-133-161544-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/c976f210828d/jci-133-161544-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/4c0c45bd6851/jci-133-161544-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/62af543d2c8c/jci-133-161544-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/e6a80e02bb5f/jci-133-161544-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/bdf7d713227a/jci-133-161544-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e67/9843051/05bcb7b5bba2/jci-133-161544-g018.jpg

相似文献

1
ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models.ODF2L 在卵巢上皮性癌细胞模型中与 WEE1 抑制作用协同致死。
J Clin Invest. 2023 Jan 17;133(2):e161544. doi: 10.1172/JCI161544.
2
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.WEE1 抑制剂 MK-1775 的临床前评估作为单一抗癌疗法。
Mol Cancer Ther. 2013 Aug;12(8):1442-52. doi: 10.1158/1535-7163.MCT-13-0025. Epub 2013 May 22.
3
Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.Myt1 上调促进癌细胞对 Wee1 抑制的获得性耐药。
Cancer Res. 2019 Dec 1;79(23):5971-5985. doi: 10.1158/0008-5472.CAN-19-1961. Epub 2019 Oct 8.
4
Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.靶向 AXL 和 mTOR 通路克服小细胞肺癌对 WEE1 抑制的原发和获得性耐药。
Clin Cancer Res. 2017 Oct 15;23(20):6239-6253. doi: 10.1158/1078-0432.CCR-17-1284. Epub 2017 Jul 11.
5
Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.奥拉帕利联合 AZD1775 通过破坏 DNA 损伤修复途径和 DNA 损伤检查点增强胃癌的抗肿瘤活性。
J Exp Clin Cancer Res. 2018 Jun 28;37(1):129. doi: 10.1186/s13046-018-0790-7.
6
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.WEE1 家族企业:调控有丝分裂、癌症进展和治疗靶标。
J Hematol Oncol. 2020 Sep 21;13(1):126. doi: 10.1186/s13045-020-00959-2.
7
Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.全基因组CRISPR-Cas9筛选揭示胶质母细胞瘤干细胞中PKMYT1和WEE1之间冗余性的丧失。
Cell Rep. 2015 Dec 22;13(11):2425-2439. doi: 10.1016/j.celrep.2015.11.021. Epub 2015 Dec 7.
8
Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.联合抑制 Rad51 和 Wee1 通过诱导与过度 DNA 损伤和复制应激相关的细胞凋亡增强头颈部鳞状细胞癌中的细胞杀伤。
Mol Cancer Ther. 2021 Jul;20(7):1257-1269. doi: 10.1158/1535-7163.MCT-20-0252. Epub 2021 May 4.
9
PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.PTEN 和 DNA-PK 决定了人乳腺癌对 WEE1 抑制的敏感性和恢复能力。
Elife. 2020 Jul 6;9:e57894. doi: 10.7554/eLife.57894.
10
Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.联合抑制 Chk1 和 Wee1:体外协同作用转化为体内肿瘤生长抑制。
Cell Cycle. 2012 Jul 1;11(13):2507-17. doi: 10.4161/cc.20899.

引用本文的文献

1
WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRAS-mutant lung cancer.WEE1抑制剂通过MYBL2-RRM2轴在KRAS突变型肺癌中与KRAS G12C抑制剂发挥协同作用。
Cell Death Dis. 2025 Aug 30;16(1):661. doi: 10.1038/s41419-025-07992-4.
2
A noncanonical role of SAT1 enables anchorage independence and peritoneal metastasis in ovarian cancer.SAT1的一种非经典作用促使卵巢癌发生锚定非依赖性和腹膜转移。
Nat Commun. 2025 Apr 3;16(1):3174. doi: 10.1038/s41467-025-58525-8.
3
Predictive value of preoperative systemic immune-inflammation index and prognostic nutrition index in patients with epithelial ovarian cancer.

本文引用的文献

1
Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.基因组和 TCR 分析数据揭示了不同上皮性卵巢癌组织学类型的独特分子特征。
Oncogene. 2022 May;41(22):3093-3103. doi: 10.1038/s41388-022-02277-y. Epub 2022 Apr 25.
2
Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.1809年至2022年及以后的卵巢癌研究视角
Diagnostics (Basel). 2022 Mar 24;12(4):791. doi: 10.3390/diagnostics12040791.
3
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.CCNE1 扩增与 PKMYT1 激酶抑制协同致死。
术前全身免疫炎症指数和预后营养指数对上皮性卵巢癌患者的预测价值。
J Ovarian Res. 2025 Mar 7;18(1):45. doi: 10.1186/s13048-025-01631-4.
4
ACAT1-Mediated ME2 Acetylation Drives Chemoresistance in Ovarian Cancer by Linking Glutaminolysis to Lactate Production.ACAT1介导的ME2乙酰化通过将谷氨酰胺分解与乳酸生成相联系,驱动卵巢癌的化疗耐药性。
Adv Sci (Weinh). 2025 Apr;12(14):e2416467. doi: 10.1002/advs.202416467. Epub 2025 Feb 14.
5
Plectin, a novel regulator in migration, invasion and adhesion of ovarian cancer.网蛋白,一种卵巢癌迁移、侵袭和黏附中的新型调节因子。
Cell Biosci. 2025 Feb 6;15(1):15. doi: 10.1186/s13578-025-01349-2.
6
Exploring the molecular interface of gene expression dynamics and prostate cancer susceptibility in response to HBCD exposure.探索在六溴环十二烷暴露下基因表达动力学与前列腺癌易感性的分子界面。
Toxicol Res (Camb). 2025 Feb 3;14(1):tfaf016. doi: 10.1093/toxres/tfaf016. eCollection 2025 Feb.
7
Exploiting Cancer Dormancy Signaling Mechanisms in Epithelial Ovarian Cancer Through Spheroid and Organoid Analysis.通过球体和类器官分析探索上皮性卵巢癌中的癌症休眠信号机制
Cells. 2025 Jan 17;14(2):133. doi: 10.3390/cells14020133.
8
Targeting WEE1 Kinase in Gynecological Malignancies.靶向妇科恶性肿瘤中的 WEE1 激酶。
Drug Des Devel Ther. 2024 Jun 20;18:2449-2460. doi: 10.2147/DDDT.S462056. eCollection 2024.
Nature. 2022 Apr;604(7907):749-756. doi: 10.1038/s41586-022-04638-9. Epub 2022 Apr 20.
4
ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer.ROS 调控的 ITPKB 磷酸化由 CAMK2G 驱动卵巢癌细胞对顺铂耐药。
Oncogene. 2022 Feb;41(8):1114-1128. doi: 10.1038/s41388-021-02149-x. Epub 2022 Jan 18.
5
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
6
Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1.顺铂介导的糖皮质激素受体激活通过 MAST1 诱导铂耐药性。
Nat Commun. 2021 Aug 16;12(1):4960. doi: 10.1038/s41467-021-24845-8.
7
Targeting cell-cycle machinery in cancer.针对癌症中的细胞周期机制。
Cancer Cell. 2021 Jun 14;39(6):759-778. doi: 10.1016/j.ccell.2021.03.010. Epub 2021 Apr 22.
8
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.WEE1 抑制剂adavosertib 治疗复发性子宫浆液性癌的 II 期研究。
J Clin Oncol. 2021 May 10;39(14):1531-1539. doi: 10.1200/JCO.20.03167. Epub 2021 Mar 11.
9
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.阿达沃西替布联合吉西他滨治疗铂耐药或铂难治性复发性卵巢癌的双盲、随机、安慰剂对照、2 期临床试验。
Lancet. 2021 Jan 23;397(10271):281-292. doi: 10.1016/S0140-6736(20)32554-X.
10
Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.威罗菲尼联合顺铂治疗转移性三阴性乳腺癌的临床疗效和分子反应相关性研究
Clin Cancer Res. 2021 Feb 15;27(4):983-991. doi: 10.1158/1078-0432.CCR-20-3089. Epub 2020 Nov 30.